Literature DB >> 16947635

Increased levels of transforming growth factor beta receptor type I and up-regulation of matrix gene program: A model of scleroderma.

Jaspreet Pannu1, Humphrey Gardner, Jeffrey R Shearstone, Edwin Smith, Maria Trojanowska.   

Abstract

OBJECTIVE: Previously published studies have demonstrated that a majority of systemic sclerosis (SSc) fibroblasts exhibit elevated levels of transforming growth factor beta type I receptor (TGFbetaRI). An experimental model that recapitulates this condition was established in control dermal fibroblasts by titrating the dose of adenovirus vector expressing TGFbetaRI (AdTGFbetaRI). The present study was undertaken to determine the functional consequences of increased levels of TGFbetaRI in SSc.
METHODS: Gene array analysis of control dermal fibroblasts transduced with AdTGFbetaRI was performed using GeneChip expression arrays. Gene validation was done by Northern blot, quantitative reverse transcriptase-polymerase chain reaction, and Western blot techniques. TGFbeta blockade was performed using soluble TGFbeta receptor. TGFbetaRI kinase/activin receptor-like kinase 5 was inhibited with pharmacologic inhibitors. TGFbetaRI and TGFbetaRII protein levels and collagen production were examined by Western blotting in primary dermal fibroblasts from 9 SSc patients and 9 healthy adults. Endogenous TGFbetaRI levels were suppressed in control and SSc fibroblasts using specific small interfering RNA (siRNA).
RESULTS: Global gene analysis indicated that a 2-fold increase in TGFbetaRI levels in control fibroblasts resulted in profibrotic changes that closely resembled the phenotype of SSc fibroblasts. A total of 125 genes were up-regulated, including COL1A1, COL1A2, and connective tissue growth factor, and 206 genes were down-regulated. Elevated production of collagen in cells transduced with AdTGFbetaRI was dependent on the autocrine TGFbeta, but not TGFbetaRI kinase activity. Eight of the 9 SSc strains exhibited increased levels of TGFbetaRI protein, which correlated with increased collagen synthesis. Treatment of SSc and matched control fibroblasts with siRNA that normalizes TGFbetaRI levels reverted collagen protein production in SSc fibroblasts to the levels observed in control fibroblasts.
CONCLUSION: Our findings demonstrate that aberrantly expressed TGFbetaRI may drive an autocrine loop involved in the up-regulation of collagen and other matrix-related genes in SSc fibroblasts.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16947635     DOI: 10.1002/art.22063

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  22 in total

Review 1.  Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities.

Authors:  Swati Bhattacharyya; Jun Wei; John Varga
Journal:  Nat Rev Rheumatol       Date:  2011-10-25       Impact factor: 20.543

Review 2.  Recent developments in myofibroblast biology: paradigms for connective tissue remodeling.

Authors:  Boris Hinz; Sem H Phan; Victor J Thannickal; Marco Prunotto; Alexis Desmoulière; John Varga; Olivier De Wever; Marc Mareel; Giulio Gabbiani
Journal:  Am J Pathol       Date:  2012-03-02       Impact factor: 4.307

Review 3.  [Pathogenesis of systemic sclerosis].

Authors:  M Fabri; T Krieg
Journal:  Hautarzt       Date:  2007-10       Impact factor: 0.751

4.  Endoglin promotes TGF-β/Smad1 signaling in scleroderma fibroblasts.

Authors:  Erin Morris; Izabela Chrobak; Andreea Bujor; Faye Hant; Christine Mummery; Peter Ten Dijke; Maria Trojanowska
Journal:  J Cell Physiol       Date:  2011-12       Impact factor: 6.384

5.  Synergistic Role of Endothelial ERG and FLI1 in Mediating Pulmonary Vascular Homeostasis.

Authors:  Agnieszka P Looney; Rong Han; Lukasz Stawski; Grace Marden; Masahiro Iwamoto; Maria Trojanowska
Journal:  Am J Respir Cell Mol Biol       Date:  2017-07       Impact factor: 6.914

6.  Therapeutic Targeting of TAZ and YAP by Dimethyl Fumarate in Systemic Sclerosis Fibrosis.

Authors:  Tetsuo Toyama; Agnieszka P Looney; Brendon M Baker; Lukasz Stawski; Paul Haines; Robert Simms; Aleksander D Szymaniak; Xaralabos Varelas; Maria Trojanowska
Journal:  J Invest Dermatol       Date:  2017-09-01       Impact factor: 8.551

7.  Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy.

Authors:  Jun Wei; Swati Bhattacharyya; Warren G Tourtellotte; John Varga
Journal:  Autoimmun Rev       Date:  2010-09-21       Impact factor: 9.754

Review 8.  Animal models of scleroderma: current state and recent development.

Authors:  Yoshihide Asano; Shinichi Sato
Journal:  Curr Rheumatol Rep       Date:  2013-12       Impact factor: 4.592

9.  Towards an anti-fibrotic therapy for scleroderma: targeting myofibroblast differentiation and recruitment.

Authors:  Andrew Leask
Journal:  Fibrogenesis Tissue Repair       Date:  2010-05-27

10.  Established neointimal hyperplasia in vein grafts expands via TGF-beta-mediated progressive fibrosis.

Authors:  Zhihua Jiang; Ming Tao; Kerri A Omalley; Danlu Wang; C Keith Ozaki; Scott A Berceli
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-07-17       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.